Carmustine
Carmustine structure
|
Common Name | Carmustine | ||
|---|---|---|---|---|
| CAS Number | 154-93-8 | Molecular Weight | 214.050 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 404ºC | |
| Molecular Formula | C5H9Cl2N3O2 | Melting Point | 30 °C(lit.) | |
| MSDS | USA | Flash Point | N/A | |
| Symbol |
GHS06, GHS08 |
Signal Word | Danger | |
|
Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system.
Nat. Commun. 6 , 6761, (2015) How the brain's antioxidant defenses adapt to changing demand is incompletely understood. Here we show that synaptic activity is coupled, via the NMDA receptor (NMDAR), to control of the glutathione antioxidant system. This tunes antioxidant capacity to refle... |
|
|
Inhibitors of hydroperoxide metabolism enhance ascorbate-induced cytotoxicity.
Free Radic. Res. 47(3) , 154-63, (2013) Pharmacological ascorbate, via its oxidation, has been proposed as a pro-drug for the delivery of H(2)O(2) to tumors. Pharmacological ascorbate decreases clonogenic survival of pancreatic cancer cells, which can be reversed by treatment with scavengers of H(2... |
|
|
Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma.
Int. J. Pharm. 495 , 972-80, (2015) In this work, multifunctional lipid nanocapsules (M-LNC) were designed to combine the activity of the cytotoxic drug paclitaxel (PTX) with the immunostimulant CpG. This nanosystem, consisting of modified lipid nanocapsules coated with a cationic polymeric she... |
|
|
Epidermal growth factor receptor variant III renders glioma cancer cells less differentiated by JAGGED1.
Tumour Biol. 36(4) , 2921-8, (2015) Glioblastoma is a highly aggressive primary brain tumor in which the majority of cancer cells are undifferentiated. One of the most common oncogenic drivers for this malignancy is the epidermal growth factor receptor variant III (EGFRvIII), which lacks a port... |
|
|
Convection enhanced delivery of carmustine to the murine brainstem: a feasibility study.
J. Neurosci. Methods 238 , 88-94, (2014) Systemic delivery of therapeutic agents remains ineffective against diffuse intrinsic pontine glioma (DIPG), possibly due to an intact blood-brain-barrier (BBB) and to dose-limiting toxicity of systemic chemotherapeutic agents. Convection-enhanced delivery (C... |
|
|
Submicron-bubble-enhanced focused ultrasound for blood-brain barrier disruption and improved CNS drug delivery.
PLoS ONE 9(5) , e96327, (2014) The use of focused ultrasound (FUS) with microbubbles has been proven to induce transient blood-brain barrier opening (BBB-opening). However, FUS-induced inertial cavitation of microbubbles can also result in erythrocyte extravasations. Here we investigated w... |
|
|
A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
ACS Nano 8(6) , 5494-514, (2014) Temozolomide (TMZ)-resistance in glioblastoma multiforme (GBM) has been linked to upregulation of O(6)-methylguanine-DNA methyltransferase (MGMT). Wild-type (wt) p53 was previously shown to down-modulate MGMT. However, p53 therapy for GBM is limited by lack o... |
|
|
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
J. Natl. Cancer Inst. 106(8) , doi:10.1093/jnci/dju170, (2014) This sixteenth biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials (RCTs) in the field of hemato-oncology, with special focus on non-Hodgkin's lymphoma. The report covers the publication... |
|
|
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Br. J. Haematol. 165(4) , 534-44, (2014) The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [HL] after a primary chemotherapy alone treatment strategy. Between 2000 and 2005, 80 children with relapsed [n = 69]... |
|
|
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
Cancer Treat. Rev. 9(4) , 313-30, (1982)
|